Ray Therapeutics, Inc.: Phase 3 study in Retinitis Pigmentosa (RP), Inherited Retinal Diseases (60 participants)
Ray Therapeutics, Inc.: Phase 3 study in Retinitis Pigmentosa (RP), Inherited Retinal Diseases (60 participants). Its enrollment of 60 is below the median of 80 (42nd percentile). Dated 8 days ago, it is in the active follow-up window. Score 80/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 60 · 42th percentile of 8,879 ClinicalTrialStartPulse records · 0.8x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Ray Therapeutics, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) |
| NCT ID | NCT07901751 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Retinitis Pigmentosa (RP); Inherited Retinal Diseases |
| Intervention types | drug, other |
| Target enrollment | 60 |
| Site countries | United States |
| Posted | 2026-10-28 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-28 |
| enrollment percentile | 42th of 8,879 (median 80, 0.8x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Ray Therapeutics, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Ray Therapeutics + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-28
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Ray Therapeutics, Inc. and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- Ray Therapeutics, Inc.'s enrollment: 42nd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
80 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Ray Therapeutics, Inc.?
Ray Therapeutics, Inc. registered a Phase 3 study (NCT07901751) in Retinitis Pigmentosa (RP) targeting 60 participants, posted 2026-10-28.
How does Ray Therapeutics, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 60 is below the median (42th percentile); smaller records often move faster and face less competition. It is fresh: dated 8 days ago, inside the window where early outreach matters most. Its Score of 80/100 puts it among the stronger signals in this feed.
Ray Therapeutics, Inc. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Ray Therapeutics, Inc. | US | 60 | 42nd | 2026-10-28 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor Ray Therapeutics, Inc. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Ray Therapeutics, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.